Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2025-04-10 Capital/Financing Update
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Navamedic has entered into an agreement in principle with Observe Medical ASA to reduce the loan receivable by 50%
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Navamedic ASA dated April 10, 2025, detailing an agreement in principle to reduce a loan receivable from Observe Medical ASA, contingent on equity injection and other creditors' actions, and potentially involving milestone payments. This concerns a specific corporate transaction (debt restructuring/financing terms) that is material enough to be disclosed as inside information under EU Market Abuse Regulation. It is not a full annual report (10-K), an earnings release (ER), or a standard dividend notice (DIV). It most closely aligns with a specific corporate action announcement. Since it details a change in financing terms and potential future payments related to a commercial agreement, 'Capital/Financing Update' (CAP) is the most appropriate fit, as it involves material changes to the company's financial assets/receivables structure. It is too specific for the general 'Regulatory Filings' (RNS) fallback.
2025-04-10 English
Navamedic Welcomes CHMP's Positive Review of Mysimba's Cardiovascular Safety
Regulatory Filings Classification · 100% confidence The document is a short press release dated April 1, 2025, announcing a positive review conclusion from the European Medicines Agency's (EMA) CHMP regarding the cardiovascular safety of the drug Mysimba. It discusses regulatory outcomes, ongoing studies, and provides contact information. It is not a full financial report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement related to product safety and regulatory status, which often falls under general regulatory news or investor relations updates. Given the content focuses on a regulatory decision and its implications, and it is not a standard financial filing, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially 'LTR' if viewed as a report on regulatory action, but RNS is the broader fallback for non-standard regulatory news. Since it is a direct announcement of a regulatory body's conclusion, RNS is the most appropriate general classification.
2025-04-01 English
Navamedic ASA: Letter received from the Norwegian Financial Supervisory Authority
Legal Proceedings Report Classification · 99% confidence The document is a short announcement from Navamedic ASA stating that they received a letter from the Norwegian Financial Supervisory Authority (NFSA) regarding misstatements in their 2023 annual and 2024 interim financial statements concerning loan accounting. This is not a full financial report (10-K or IR), nor is it a standard earnings release (ER) or a management discussion (MDA). It specifically details an update on a regulatory/legal matter concerning past financial reporting accuracy. This fits best under 'Legal Proceedings Report' (LTR) as it concerns regulatory action/inquiry regarding financial statements, or potentially 'Regulatory Filings' (RNS) as a general regulatory update. Given the nature of the communication—a direct response to a regulatory body's findings about accounting errors—LTR is a strong candidate, but since it is an announcement about receiving a letter concerning financial statements rather than the legal proceeding itself, and it is a general regulatory communication, RNS (Regulatory Filings) serves as the most appropriate general category for miscellaneous regulatory updates that don't fit the specific financial report types. However, since it directly addresses issues found in the 'annual financial statements for 2023' and 'interim financial statements for 2024', it is closely related to financial reporting scrutiny. Given the options, and that it is a specific regulatory communication about financial reporting integrity, LTR (Legal Proceedings Report) captures the essence of the regulatory challenge better than the generic RNS, although RNS is also plausible. I will classify it as LTR due to the nature of the regulatory inquiry into accounting practices.
2025-03-28 English
Navamedic ASA: Mandatory notice of trade
Director's Dealing Classification · 100% confidence The document text details a transaction involving a 'person discharging managerial responsibilities' (Rune Wahl, a Board member) in the issuer's shares (Navamedic ASA). Specifically, it reports that the individual 'Bought shares' and provides the price, volume, date, and location of the transaction. This structure perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2025-03-19 English
Navamedic ASA: Mandatory notice of trade
Director's Dealing Classification · 100% confidence The document is titled 'Navamedic ASA: Mandatory notice of trade' and explicitly states that a 'Board member and Primary Insider' has acquired shares. It references disclosure requirements under the Market Abuse Regulation (MAR) Article 19. This content directly corresponds to the reporting of personal share transactions by company directors and executives (insider trades), which matches the definition for Director's Dealing (DIRS). The document length is very short (732 chars), but the content is a direct notification of a trade, not just an announcement that a report is available, making DIRS a more specific fit than RPA or RNS.
2025-03-19 English
Navamedic ASA: Mandatory notice of trade
Director's Dealing Classification · 100% confidence The document text details a transaction involving shares of Navamedic ASA by an individual identified as a 'Primary insider: Commercial Director' (Philip Slätis). Section 4 explicitly describes the 'Nature of the transaction' as 'Bought shares' and provides details on price, volume, date (10.03.2025), and location (Oslo Stock Exchange). This structure is characteristic of mandatory reporting for insider trading or director's dealings, which corresponds to the Director's Dealing (DIRS) filing type.
2025-03-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.